Stock Research for VRX

Featured Broker: Ally Invest

Get the due diligence for another stock.

 

VRX Stock Chart & Research Data

The VRX chart settings shown below allow you to select time intervals of 1 min, 30 mins, an hour or by day - week - month. There is also the ability to change the VRX chart style to candles, hollow candles, bars, lines or add various indicators. You can even add a symbol and compare history.


 


VRX Due diligence Resources & Stock Charts

The VRX stock resources shown below were gathered to cut back on time by allowing you to visit multiple sites at once. For your convenience each link clicked will open in a window. In addition to the individual links there is a button at the bottom that will allow you to open all the links at the same time. Note opening all links at once may not work with all browsers. Some browsers block multiple windows, to resolve this please allow that site to use pop-ups.

The Four Most Popular Resources

CNN View VRX Detailed Price Forecast - CNN Money CNN View VRX Detailed Summary - Google Finance
Yahoo View VRX Detailed Summary - Yahoo! Finance Zacks View VRX Stock Research & Analysis - Zacks.com

Stock Analysis

TradeIdeas View VRX Trends & Analysis - Trade-Ideas Barrons View VRX Major Holders - Barrons
NASDAQ View VRX Call Transcripts - NASDAQ Seeking View VRX Breaking News & Analysis - Seeking Alpha
Spotlight View VRX Annual Report - CompanySpotlight.com OTC Report View VRX OTC Short Report - OTCShortReport.com
TradeKing View VRX Fundamentals - TradeKing Charts View VRX SEC Filings - Bar Chart
WSJ View Historical Prices for VRX - The WSJ Morningstar View Performance/Total Return for VRX - Morningstar
MarketWatch View the Analyst Estimates for VRX - MarketWatch CNBC View the Earnings History for VRX - CNBC
StockMarketWatch View the VRX Earnings - StockMarketWatch MacroAxis View VRX Buy or Sell Recommendations - MacroAxis
Bullish View the VRX Bullish Patterns - American Bulls Short Pains View VRX Short Pain Metrics - ShortPainBot.com

Social Media Mentions

StockTwits View VRX Stock Mentions - StockTwits PennyStocks View VRX Stock Mentions - PennyStockTweets
Twitter View VRX Stock Mentions - Twitter Invest Hub View VRX Investment Forum News - Investor Hub
Yahoo View VRX Stock Mentions - Yahoo! Message Board Seeking Alpha View VRX Stock Mentions - Seeking Alpha


Financial & Transaction Holdings

SECform4 View Insider Transactions for VRX - SECform4.com Insider Cow View Insider Transactions for VRX - Insider Cow
CNBC View VRX Major Holdings Summary - CNBC OTC Markets View Insider Disclosure for VRX - OTC Markets
Yahoo View Insider Transactions for VRX - Yahoo! Finance NASDAQ View Institutional Holdings for VRX - NASDAQ


Stock Charts

FinViz View VRX Stock Insight & Charts - FinViz.com StockCharts View VRX Investment Charts - StockCharts.com
BarChart View VRX Stock Overview & Charts - BarChart Trading View View VRX User Generated Charts - Trading View




Latest Financial News for VRX


Bausch + Lomb Receives 510(K) Clearance From FDA For Bausch + Lomb Ultra® Multifocal For Astigmatism Contact Lenses
Posted on Wednesday December 05, 2018

BRIDGEWATER, N.J., Dec. 5, 2018 /PRNewswire/ -- Bausch + Lomb, a leading global eye health company and wholly owned subsidiary of Bausch Health Companies Inc. (NYSE/TSX: BHC), today announced that it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for Bausch + Lomb ULTRA® Multifocal for Astigmatism contact lenses, the first multifocal toric lens to be available as a standard offering in the eye care professional's fit set. "Eye care professionals have routinely stressed the need to have a readily available contact lens that addresses both presbyopia and astigmatism, underscoring the critical vision needs of this growing patient population," said Joe Gordon, U.S. president, Bausch + Lomb.


VRX Escrow Corp. -- Moody's upgrades Bausch Health's CFR to B2 from B3; stable outlook
Posted on Friday November 09, 2018

Moody's Investors Service ("Moody's") upgraded the ratings of Bausch Health Companies Inc. ("Bausch Health") including the Corporate Family Rating to B2 from B3, the Probability of Default Rating to B2-PD from B3-PD, the senior secured rating to Ba2 from Ba3 and the senior unsecured rating to B3 from Caa1. "The upgrade reflects continued progress in Bausch Health's turnaround including organic growth in major business lines, resolution of the Xifaxan patent challenge, and Moody's expectation for continued debt reduction," stated Michael Levesque, Moody's Senior Vice President.


Bausch Health Launches ALTRENO™ (tretinoin) Lotion, 0.05% In The United States
Posted on Tuesday October 30, 2018

LAVAL, Quebec, Oct. 30, 2018 /PRNewswire/ -- Bausch Health Companies Inc. (NYSE/TSX: BHC) and its dermatology business, Ortho Dermatologics, one of the largest prescription dermatology health care businesses, today announced the U.S. launch of ALTRENOTM (tretinoin) Lotion, 0.05% for the topical treatment of acne vulgaris in patients 9 years of age and older. ALTRENO Lotion is the first and only tretinoin available in a lotion for acne.


Bausch Health Announces Publication Of Pivotal Phase 3 Efficacy And Safety Data On ALTRENO™ (tretinoin) Lotion, 0.05% In The Journal Of Drugs In Dermatology
Posted on Thursday October 11, 2018

LAVAL, Quebec, Oct. 11, 2018 /PRNewswire/ -- Bausch Health Companies Inc. (NYSE/TSX: BHC) and its dermatology business, Ortho Dermatologics, one of the largest prescription dermatology health care businesses, today announced that the Journal of Drugs in Dermatology has published results of two identical Phase 3, multicenter, randomized, double-blind, vehicle-controlled, parallel group studies examining the efficacy and safety of ALTRENOTM (tretinoin) Lotion, 0.05%, the first formulation of tretinoin, a retinoid, in a lotion indicated for the topical treatment of acne vulgaris in patients 9 years of age and older.1 The U.S. Food and Drug Administration approved the New Drug Application for ALTRENO Lotion on Aug. 24, 2018. In the studies, ALTRENO Lotion was shown to have significantly greater efficacy compared to vehicle in achieving treatment success, which was defined as at least a two-grade improvement from baseline in a global severity by Evaluator Global Severity Score (EGSS) and 'clear' or 'almost clear' skin.


Stock Market & Investing Books

Enter a stock symbol to view the stock details.